Oncolytics Biotech (ONCY) Positive Data On Its Proprietary Formulation

Oncolytics Biotech Inc. (Nasdaq:ONCY)

ONCY reported a poster presentation containing updated efficacy data from a Phase 2 study examining the use of its proprietary formulation of the human reovirus REOLYSIN(R), in combination with carboplatin and paclitaxel in patients with stage IV non-small cell lung cancer with Kras or EGFR-activated tumors (REO 016) was made at International Association for the Study of Lung Cancer.

The poster presentation included new efficacy data that correlated a number of molecular abnormalities with best response, progression free survival and one-year survival.

This is the first time ONCY has reported data correlating the presence of specific biomarkers with efficacy, which covers both best response and survival in patient tumours with a Ras-activated pathway.

According to ONCY , although the study examined a relatively small number of patients, this data is encouraging, especially in light of a growing focus among healthcare professionals on personalizing cancer treatment based on tumour type.

Lung cancer is by far the leading cause of cancer death among both men and women. The American Cancer Society estimates that in 2013, approximately 228,190 new cases of lung cancer will be diagnosed. Between 85% and 90% of all lung cancers are classified as non-small cell lung cancer; squamous cell carcinomas account for 25-30% of all lung cancers.

ONCY is a biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.

More about Oncolytics Biotech Inc. (Nasdaq:ONCY) at www.oncolyticsbiotech.com .

*****

Crown Equity Holdings Inc. (CRWE)

CRWE recently reported that it is looking to deliver value for its stockholders in both the near and long term.

For that reason, CRWE is refocusing its strategic plan for future growth and services with its original online business-to-business (B2B) marketplace platform for manufacturers and small to large businesses on a global basis to sell and acquire various types of merchandise; strategic plans are also being developed for CRWE ’s online video-sharing project to improve the potential future growth for the company.

When B2B e-commerce began in the early 1990s, no one expected the growth explosion it experienced in the latter part of the decade. The B2B industry generates billions of dollars and thousands of jobs worldwide.

The increased use of video advertising and also video viewing continued again in 2013 and will increase again and again for the next five or so years according to industry trends. According to Break Media, video ad spending will reach $5.4 Billion by 2016.

CRWE is targeting these multi-billion dollar markets with its iB2BGlobal project and its Division CRWETube ( www.crwetube.com ).

Together with its digital network of websites, CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher. CRWE focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com .

********************************

Read Full Disclaimer at www.pennyomega.com/disclaimer